Td Asset Management Inc Corvus Pharmaceuticals, Inc. Transaction History

Td Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$1.74 - $5.98 $23,634 - $81,226	-13,583 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$2.56 - $5.44 $76,787 - $163,172	-29,995 Reduced 68.83%	13,583 $74,000
Q3 2019 Nov 07, 2019	SELL	$3.01 - $6.5 $18,060 - $39,000	-6,000 Reduced 12.1%	43,578 $131,000
Q2 2019 Aug 01, 2019	BUY	$3.3 - $4.58 $7,260 - $10,076	2,200 Added 4.64%	49,578 $185,000
Q1 2019 May 08, 2019	BUY	$3.75 - $4.97 $1,125 - $1,491	300 Added 0.64%	47,378 $190,000
Q4 2018 Feb 01, 2019	BUY	$3.29 - $8.94 $1,974 - $5,364	600 Added 1.29%	47,078 $173,000
Q3 2018 Nov 01, 2018	BUY	$8.58 - $11.4 $15,444 - $20,520	1,800 Added 4.03%	46,478 $399,000
Q2 2018 Jul 31, 2018	BUY	$9.42 - $13.73 $3,768 - $5,492	400 Added 0.9%	44,678 $491,000
Q1 2018 May 11, 2018	BUY	$7.48 - $11.53 $331,199 - $510,525	44,278 New	44,278 $511,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.